Cartilage damage in the knee aﬀects millions of people worldwide with a continued rise in incidence. Currently, the only conventional solutions are symptoms (pain, stiﬀness) management, microfracture and in the end, replacing the joint with a prosthesis. Lately, cell therapies have emerged as a solution to regenerate cartilage e.g. tissue engineered autologous chondrocyte implantations (ACIs). However, ACIs often fail to integrate with the surrounding tissue, which results in failure rates up to 36%. Lamina’s new cell therapy from the Strasbourg University and Inserm aims to improve the cell approach by an innovative scaﬀold that houses Mesenchymal stem cells (MSCs) for optimal regeneration of the cartilage. By combining this patented scaﬀold together with growth factors and the MSCs, the product ensures fast recovery and high quality cartilage.
NLC and Medtech Europe publish reflection paper on how to improve the innovative landscape of Europe in health tech
MedTech Europe in collaboration with NLC published a reflection paper outlining how Europe can provide a more attractive landscape for Innovation in health tech….
Unleash the potential of healthtech innovation. Together.
Ever since the Covid-19 crisis started, NLC has adopted the strategy “prepare for the worst, prepare for the best”. Now, six months later, we…
4 NLC Ventures shortlisted for 2020 Academic Startup Competition
Out of a total of 20 ventures that have been shortlisted for the 2020 Academic Startup Competition, no less than 4 are ventures from…